Figure 2.

Inhibition/inactivation of ABL1 and ABL2 results in medulloblastoma cell death and decreased expression of c-MYC. (A) Dose–response curves of D283 and D556 medulloblastoma cells treated for 18 hours with cisplatin, a mainstay alkylating agent for the adjuvant treatment of medulloblastoma; the ABL allosteric inhibitor, asciminib; and the nonselective tyrosine kinase inhibitor, nilotinib. The combination of nilotinib and asciminib was the most lethal. (B) Representative Western blot demonstrating the time- and dose-dependent decrease in expression of c-MYC when treated with the ABL allosteric inhibitor GNF5. (C) Western blot of ABL1/2 knockdown cells (283 AAn) demonstrating decreased c-MYC expression compared to scrambled controls (283 SCn).